Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate Oct 24, 2024
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024 Oct 22, 2024
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers Oct 15, 2024
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers Oct 7, 2024
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr Sep 12, 2024
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers Aug 21, 2024
Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr Aug 14, 2024
